Abstract
This systematic review and meta-analysis protocol aims to investigate the association between concurrent hepatic steatosis and the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (HBV) or hepatitis C (HCV) virus infection. Non-alcoholic fatty liver disease (NAFLD) is a prevalent cause of chronic liver disease, often co-occurring with viral hepatitis due to the global rise in obesity and type 2 diabetes. While both conditions independently contribute to liver damage, their synergistic effect on HCC risk remains inconclusive. This study will synthesize evidence from case-control and cohort studies to determine if hepatic steatosis is an independent risk factor for HCC in this population.
Introduction
Chronic infection with HBV or HCV is a primary driver of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Concurrently, the global prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is rising, creating a "syndemic" where viral hepatitis and metabolic liver disease overlap. Hepatic steatosis—the accumulation of fat in the liver—is a hallmark of NAFLD and is known to induce inflammation and oxidative stress.
The "Double Hit" hypothesis suggests that viral infection (Hit 1) and metabolic stress from steatosis (Hit 2) may act synergistically to accelerate progression to malignancy. However, existing observational studies have yielded conflicting results regarding whether concurrent steatosis significantly increases HCC risk. This systematic review is designed to provide a definitive synthesis of the available evidence to guide clinical management and cancer surveillance strategies.
Methods
This study follows a pre-defined protocol for a systematic review and meta-analysis of observational studies.
Search Strategy and Inclusion Criteria
The researchers will conduct comprehensive searches of PubMed, Scopus, and Web of Science databases using keywords related to "fatty liver," "hepatitis," and "liver neoplasm." Eligible studies include case-control or cohort designs where hepatic steatosis was diagnosed via histology (biopsy) or medical imaging (ultrasound, CT, or MRI) in patients with chronic HBV or HCV.
Data Extraction and Quality Assessment
Data regarding study design, population characteristics, and risk estimates (Odds Ratios, Risk Ratios, or Hazard Ratios) will be extracted. The quality of included observational studies will be assessed using the Newcastle-Ottawa Scale (NOS) to identify potential sources of bias.
Statistical Analysis
A random-effects model will be employed to pool risk estimates, accounting for anticipated heterogeneity across different study populations and methodologies. Subgroup analyses will be performed based on the type of viral infection (HBV vs. HCV) and the method of steatosis diagnosis.
Discussion and Limitations
Determining the independent risk posed by hepatic steatosis in the context of viral hepatitis is crucial for personalized medicine. If a significant association is confirmed, it would underscore the importance of metabolic health management (e.g., weight loss, diabetes control) alongside antiviral therapy for HCC prevention.
Several limitations are anticipated. The reliance on observational data introduces potential confounding by factors such as alcohol consumption or smoking. Furthermore, the varying sensitivity of diagnostic tools for steatosis (imaging vs. histology) may introduce heterogeneity. Sensitivity analyses are planned to address these issues.
Conclusion
This protocol establishes a rigorous framework for evaluating the impact of concurrent hepatic steatosis on HCC risk in patients with viral hepatitis. The findings will clarify whether metabolic liver fat serves as a critical "second hit" in liver carcinogenesis, potentially leading to updated clinical guidelines for high-risk patient monitoring.
Summary updated